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This issue of Mayo Clinic Proceedings contains an important report by De Simone et. al. that 
investigates the impact of the 2007 American Heart Association (AHA) guidelines on the 
prescribing of antibiotic prophylaxis (AP) by dentists to protect patients at risk of infective 
endocarditis (IE) from developing the disease following invasive dental procedures.1  
Infective endocarditis affects the endocardial lining of the heart, particularly the valve 
leaflets, and has a yearly incidence of 3-10 per 100,000 in most parts of the world.2 It is 
characterized by the development of infected heart valve vegetations, and prognosis is poor, 
with 15-20% mortality during the initial hospital admission, increasing to approximately 30% 
by the end of the first year.2 The concept that bacteria released into the circulation during 
invasive dental procedures might cause IE was first suggested by Lewis and Grant in 1923,3 
and in 1935 Okell and Elliott4 discovered that following dental extractions 61% of patients 
had a positive blood culture for oral viridans group Streptococci. The latter group also found 
that oral viridans group Streptococci could be isolated from the damaged heart tissue of 40-
45% of IE cases they examined.3 
In 1955, soon after antibiotics became widely available, the AHA produced the first 
guidelines recommending the use of AP to prevent IE in those considered at risk of the 
disease and who were undergoing invasive procedures (including dental procedures). Over 
time, AP recommendations have become simpler and more focussed. Prior to 2007, AHA 
guidelines recommended AP for those undergoing invasive dental procedures who were 
considered at high-risk or moderate-risk of developing IE, but in 2007 the AHA 
recommended that it should be given only to those at high-risk.5 In 2009, the European 
Society of Cardiology (which sets guidance for most of Europe),6 and most other guideline 
committees around the world, followed suit. The exception was the United Kingdom, where 
the quasi-governmental National Institute for Health and Care Excellence (NICE) 
recommended the complete cessation of AP in 2008.7 This decision was based on the lack of 
randomized placebo controlled trial (RCT) evidence to support the efficacy of AP and their 
assessment of the lack of cost-effectiveness of AP. 
The best evidence for AP efficacy would come from a RCT. Unfortunately, a RCT has never 
been performed and it is unlikely one will be performed in the foreseeable future. AP is a 
prevention strategy, and IE is comparatively rare. This means that hundreds of patients at risk 
of endocarditis would need to receive AP to prevent one case, and many thousands of 
individuals at risk of endocarditis would need to be randomized to placebo or prophylaxis to 
have sufficient statistical power to detect an effect.8 This means that the size, cost, and 
complexity of a RCT would be enormous. A further barrier is the ethical concern about 
randomizing individuals at risk of endocarditis to placebo. 
An alternative is to use observational studies to see if changes in AP guidelines have altered 
the incidence of IE, and several studies have done this. DeSimone et al refer to the 
observational study by Dayer et al.9 This study used administrative data for the whole of 
England to study the effect of the 2008 NICE guidelines on the prescribing of AP and the 
incidence of IE in England. It found an 89% decrease in AP prescribing and a significant 
increase in the incidence of IE. As observational data, however, the Dayer et al research did 
not prove a cause-and-effect relationship between these changes and the 2008 NICE 
guidance, and therefore did not meet the criteria set by NICE to change its guidance. 
Nonetheless, following further debate, as well as the publication of data showing the low 
incidence of adverse drug reactions with AP10 and the cost-effectiveness of AP,11 NICE 
amended its guidance in 2016 to make clear that in individual cases antibiotic prophylaxis 
may be appropriate.12 
The Dayer et al study also showed the very large population needed to achieve the statistical 
power to identify a significant increase in the incidence of IE associated with changes in AP 
prescribing.9 In the Dayer et al study, NICE guidance changed from recommending AP for 
moderate- and high-risk individuals to recommending no AP. The population needed to 
power a study looking at a change from recommending AP for those at moderate- and high-
risk of IE to recommending it just for those at high-risk would be even larger than the number 
needed to power the Dayer et al study.  Unfortunately, several of the studies that claimed to 
demonstrate no change in the incidence of IE following AHA or European Society of 
Cardiology guideline changes were underpowered to detect a change.13 This means we 
cannot be sure if there really was no change in IE incidence or if the lack of change was 
caused by the study having insufficient power to detect it. It is important therefore to ensure 
such studies are adequately powered. 
Recently, several studies have, like the Dayer et al study, used large administrative data sets 
to increase the population size being studied when looking at the effect of the AHA or 
European Society of Cardiology guideline changes, and some have claimed to demonstrate a 
significant increase in IE.14-17 Again however, it is impossible to prove a cause-and-effect 
relationship with observational studies like this. In addition, studies to date, (with the 
exception of the Dayer et al study) have lacked data to demonstrate the size and timing of any 
associated change in AP prescribing. Accompanying AP prescribing data is essential for any 
study that intends to claim that a guideline change had no effect on IE incidence. No change 
in incidence could simply be the result of no change in AP prescribing. Prescribing data are 
also essential for the power calculations needed to demonstrate that a study has the statistical 
power to detect a change. Even when AP prescribing data are available, failure of patient 
compliance in taking AP could confound attempts to prove AP efficacy. 
The DeSimone et al study is the first from North America to show that the 2007 AHA 
guideline change did indeed result in a highly significant reduction in AP prescribing by 
dentists, and this is an important first. Indeed, the size and timing of the change was closely 
similar to that observed in England.9 If the small number of dentists studied reflects the 
response of dentists nationwide, this suggests a high level of compliance with the AHA 
guideline change. 
DeSimone et al also identified some concerns, however. Although there was the expected fall 
in AP prescribing for those at moderate-risk of IE, they also identified a significant reduction 
in AP prescribing for those at high-risk. Specifically, the proportion of high-risk individuals 
who should have received AP decreased from 96.9% before 2007 to 81.3% (P=0.02) after, 
suggesting that a significant proportion of those who should have received AP did not. The 
fall was even larger, from 98% to 80.2% (P=0.03), for dental cleaning visits. This is worrying 
since a whole mouth dental cleaning (a.k.a. scaling) is one of the most bacteremia-inducing 
dental procedures, particularly in those with poor oral hygiene. 
On the other hand, a reduction in AP prescribing for non-indicated dental procedures from 
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THE FORMULATION OF PROOFS suggests that the description of those dental procedures 
that should be covered by AP are much clearer in the 2007 AHA guidelines than before. 
The decrease in AP prescribing to those at high-risk of IE since the 2007 guidelines and the 
continued prescribing of AP to 8.6% of individuals at moderate risk of IE (noted in the 
DeSimone et al study) mirrors similar findings in a study of Canadian dentists and 
hygienists18 and suggests some difficulty on the part of dentists in distinguishing high-risk 
from moderate-risk patients. This is perhaps not surprising since the categorization of patients 
is based on cardiological diagnoses and procedures that, whilst familiar to cardiologists, are 
not familiar to many dentists. In particular, congenital and native valve conditions and more 
complex cardiac repair procedures can be difficult for a non-cardiologist to categorize, and 
the dentist is frequently reliant on the SDWLHQW¶Vunderstanding of his condition, which is often 
poor, to categorize it.  
As concluded by DeSimone et al, continued medical education of dentists and other 
clinicians is needed to better ensure compliance with national guidelines. But simplification 
of risk stratification and the terminology used to describe it would also help. Perhaps most 
important, however, would be better communication between cardiologists and dentists. 
Cardiologists are best placed to identify the risk status of their patient and the need for AP, 
while the dentist is best placed to identify when a risk prone dental procedure needs to be 
performed and, therefore, when AP is needed. Clear and direct communication between 
cardiologist and dentist is therefore essential. Patients also need to be fully informed of their 
risk status and the potential benefits and disadvantages of AP, so that they can participate in 
the decision making. Again this is perhaps a discussion best undertaken by the cardiologist, 
but it is clearly very important that the dentist is kept fully informed. 
In conclusion, DeSimone et al have published an interesting study that reports for the first 
time the high level of compliance by dentists with the most recent AHA guidelines on AP 
prescribing. This is critical information that needs to be validated on a larger scale. Such 
additional data are needed to support large administrative data studies on the incidence of IE, 
if we are to understand the real impact of the 2007 AHA guideline changes. Importantly, the 
DeSimone et al study also helps us to identify deficiencies in guideline compliance, as well 
as possible ways to improve clinical practice. 
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